Moreover, treatment with a monoclonal VEGFC antibody reduced the clonogenic capacity of CD34-positive AML blasts, and induced their differentiation via the suppression of FOXO3A and inhibition of MAP/ERK (79) (Table 1). The gene discussed is CD34; the disease is acute myeloid leukemia.